Navigation Links
InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
Date:9/16/2008

- Biotech Begins to Demonstrate Strategy to Expand NHL Marketplace with Novel Antibody and Speedy DXL Screening Preclinical Development Program -

BRITISH COLUMBIA, Canada, Sept. 16 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (TSX VENTURE: IXS; OTC Bulletin Board: IXSBF; http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL(TM)), announced today the results of an extensive mouse tumor study demonstrating superiority of InNexus' DXL625 (CD20) versus Rituxan(R) in the xenograft model.

InNexus plans to submit the data for publication along with additional data from animal studies recently completed and presented at the American Association for Cancer Research (AACR) 2008 Annual Conference. The company has also launched a large scale study of DXL625 with primates, designed to evaluate toxicity and pharmokinetics, enabling the company to move the product to the FDA toward human testing.

"A study performed by an independent group investigating the survival of mice intravenously injected with B-lymphoma cells and treated subsequently with DXL625 showed a significant improvement in outcome compared to animals treated with equivalent doses of Rituxan(R), a commercially available anti-CD20 antibody," said Dr. Thomas Kindt, InNexus' Chief Scientific Officer. "Animals treated with either drug had a superior outcome when compared to those receiving inactive control (vehicle), however DXL625 had a substantial advantage over the competing antibody. We are confident that these results will translate to therapeutic advantage when DXL625 is used in human subjects."

"The DXL(TM) technology platform builds better antibodies and soon you'll be able to see our strategy to expand the NHL marketplace. We enhance an antibody's potency in a real, measurable and predictable fashion," said Jeff
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
3. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
7. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
8. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
9. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... BioElectronics Corporation (OTC Pink: BIEL), the ... medical devices, announced today that its registry study ... device has been published in the prominent peer ... http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than 5,000 chronic pain sufferers ... Chronic pain is a major ...
(Date:8/4/2015)... , Aug. 4, 2015  ContraVir Pharmaceuticals, Inc. ... on the development and commercialization of targeted antiviral ... Executive Officer, will present live at VirtualInvestorConferences.com on ... 6, 2015 TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... live, interactive online event where investors are invited ...
(Date:8/4/2015)... Wis. , Aug. 4, 2015  Ironshore ... agreement with Restore Health, a company specializing in ... a double-blind clinical trial, designed to evaluate the ... in development to treat Attention-deficit/hyperactivity disorder (ADHD). This ... Restore Health originally partnered with Ironshore ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2
... Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... President and Chief Executive Officer, will provide an overview ... Piper Jaffray Health Care Conference on Wednesday, November 30, ... Palace Hotel in New York. The presentation will be ...
... Nov. 21, 2011 Reportlinker.com announces that a ... catalogue: The 2011 Vibrio Diagnostics ... Forecasts by Country http://www.reportlinker.com/p0444741/The-Vibrio-Diagnostics-Market-US-Europe-JapanTest-Volume-and-Sales-Forecasts-by-Country.html ... detailed analysis of the Vibrio diagnostics market in ...
Cached Medicine Technology:The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 2The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 3The 2011 Vibrio Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country 4
(Date:8/4/2015)... Angeles, CA (PRWEB) , ... August 04, 2015 , ... ... study that found financial incentives to be a viable method for encouraging people to ... wager money on the future of their weight loss success, adding a financial incentive ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of Local Food,” scheduled for Nov. 3 – 4, 2015, at UC San ... sustainably, create new businesses, improve food access, and manage resources efficiently against the ...
(Date:8/4/2015)... ... 04, 2015 , ... Members receiving care from a doctor who participates in ... that is nine percent lower -- than those members at traditional doctor practices, according ... programs. , “The promise of patient-centered, or value-based, care to deliver better quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... Increasingly, patients are researching online ... physician. In an effort to share more and better information with these savvy ... publicly share patient satisfaction ratings and comments about its doctors and advanced practice ...
Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3
... you are pregnant, here,s another reason to work out: ... developing neurodegenerative diseases, such as Alzheimer,s, later in life. ... FASEB Journal ( http://www.fasebj.org ) shows that mice ... Alzheimer,s disease showed fewer signs of the disease and ...
... of the leading causes of death and morbidity worldwide, ... 2008, the worldwide cost of cancer due to premature ... to be US$895 billion. An expert report from ... of some of the world,s leading cancer specialists, from ...
... Netherlands: Mothers who are exposed to particular agents during pregnancy ... asthma, according to new research. The study will ... Society,s Annual Congress in Amsterdam. It is ... and chemicals it can cause asthma. However, there has been ...
... The Netherlands: A new study has shown that people ... reduced lung function are at a serious risk of ... presented today (26 September 2011) at the European Respiratory ... COPD and reduced lung function should be routinely screened ...
... and unspoken clues exchanged by patients and doctors exert ... study by the University of Michigan Health System. Researchers ... interviews with participants to help elucidate signals sent and ... The method shows promise for improving medical decision ...
... of personalised medicine, gains in cancer survival over the ... trials with less stringent evidence criteria, a researcher told ... 26 Sept). The introduction of targeted treatments means ... most effective way of getting new treatments to cancer ...
Cached Medicine News:Health News:Pregnant women who exercise protect their offspring against long-term neurodegenerative diseases 2Health News:Unequal access to cancer care can no longer be tolerated 2Health News:Unequal access to cancer care can no longer be tolerated 3Health News:A mother's occupation while pregnant can cause asthma in children 2Health News:New evidence highlights risk of comorbidities for COPD patients 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 2Health News:Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds 3Health News:Smaller, faster trials can improve cancer patient survival 2Health News:Smaller, faster trials can improve cancer patient survival 3
BD Beaver implant blade, 5.1 mm, angled 45, bevel up. matte finish. Designed for widening the incision for lens implantation. Beaver implant blades put precision and control in your hands, sterile....
BD Beaver Sickle Edge blade, straight, 5.0 mm W x 84 mm long. Specially designed for superior visibility and easy access into the ear canal, sterile....
BD Beaver Meniscus blade, 7 mm flat (4/bx, 1 bx/ca), specially designed maximum leverage and visibility, cutting edge: 7 mm, sterile....
RM-1970 Mucotome ergonomic design with E-Type coupling, designed for mucosal repair surgery....
Medicine Products: